Additionally, enoblituzumab, a humanized monoclonal antibody targeting B7‐H3, demonstrated acceptable safety and antitumor effect when combined with pembrolizumab in early clinical trials for head and neck squamous cell carcinoma (HNSCC) and non‐small cell lung cancer (NSCLC) [60]. Here, CD276 is linked to head and neck squamous cell carcinoma.